FAS and periventricular leukomalacia: While, inhibition of IL-6R with Tocilizumab suppressed Fas/FasL levels without affecting the TNF-α/TNFR1 and TRAIL/DR4/DR5 induction, although it did alleviate mucosal epithelial apoptosis in PVL-treated mice (Fig. 2c, d).